Skip to main content

Table 2 Analysis of discontinuations by comparator, in studies of adverse events associated with celecoxib in arthritis

From: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

    Number of Incidence of events (%)   
Outcome and comparisons Celecoxib daily dose Comparator and daily dose Trials Patients Celecoxib Comparator Relative riska (95% CI) NNTpb or NNHc (95% CI)
All-cause discontinuation         
Celecoxib v placebo Any Placebo 19 9,919 28 40 0.64 (0.61–0.68) a 8.4 (7–10) b
Celecoxib v paracetamol Any Paracetamol 4,000 mg 2 1,056 17 25 0.69 (0.54–0.88) a 13 (8–35) b
Celecoxib v rofecoxib Any Rofecoxib 25 mg 5 2,671 14 14 1.0 (0.8–1.2)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 19 22,616 23 23 0.96 (0.91–1.01)  
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 20 31,711 31 34 0.96 (0.93–0.99) a 28 (22–40) b
Celecoxib (any dose) v any active Any Any active comparator 26 35,302 29 32 0.95 (0.92–0.98) a 36 (27–57) b
Lack-of-efficacy discontinuation        
Celecoxib v placebo Any Placebo 19 9,914 17 28 0.53 (0.49–0.57) a 9.0 (8–11) b
Celecoxib v paracetamol Any Paracetamol 4,000 mg 2 1,056 7.2 11 0.66 (0.45–0.97) a 27 (14–390) b
Celecoxib v rofecoxib Any Rofecoxib 25 mg 5 2,671 2.2 1.5 1.5 (0.84–2.6)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 19 22,613 8.0 6.3 1.1 (1.02–1.23) a 58 (42–97)c
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 20 31,708 11.3 10.4 1.02 (0.96–1.1)  
Celecoxib (any dose) v any active Any Any active comparator 26 35,299 10.6 9.6 1.0 (0.95–1.1)  
Adverse-event discontinuation         
Celecoxib v placebo Any Placebo 19 9,914 6.6 5.5 1.2 (0.97–1.4)  
Celecoxib v paracetamol Any Paracetamol 4,000 mg 2 1,056 4.3 5.4 0.81 (0.47–1.4)  
Celecoxib v rofecoxib Any Rofecoxib 25 mg 5 2,662 6.2 6.8 0.91 (0.68–1.2)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 19 22,613 8.5 9.9 0.84 (0.77–0.92) a 74 (47–180) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 20 31,708 11.4 14.6 0.86 (0.81–0.91) a 31 (25–41) b
Celecoxib (any dose) v any active Any Any active comparator 26 35,299 10.9 13.5 0.87 (0.82–0.92) a 38 (30–51) b
Gastrointestinal-adverse-event discontinuation       
Celecoxib v placebo Any Placebo 11 5,933 2.5 2.0 1.2 (0.8–1.7)  
Celecoxib v paracetamol Any Paracetamol 4,000 mg 2 726 1.6 2.6 0.6 (0.2–1.6)  
Celecoxib v rofecoxib Any Rofecoxib 25 mg 5 2,671 2.2 2.9 0.7 (0.5–1.2)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 11 18,639 4.8 6.5 0.7 (0.6–0.8) a 58 (42–98) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 12 27,299 6.4 9.6 0.75 (0.7–0.8) a 31 (26–40) b
Celecoxib (any dose) v any active Any Any active comparator 18 30,560 6 8.7 0.75 (0.7–0.8) a 37 (30–48) b
  1. aRelative risk: bold indicates statistically significant difference. bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.